FAM111B promotes prostate cancer progression by inhibiting apoptosis via ATF3 suppression and MAPK pathway activation: a novel biomarker and therapeutic target Authors: Yanan Wang, Zefeng Wang, Zhen Yin, Tianbao Song, Yipeng He, Ming Li, Zitao Wang, Zhongze Li, Peihan Wang, Zhiquan Hu, Zhihua Wang, Weimin Yu, Fan Cheng Published: 2025 ABSTRACT AbstractBackgroundProstate cancer (PCa) ranks among the most prevalent and aggressive malignancies in men worldwide, with its incidence continuing to rise. This study investigates the role of FAM111B in PCa progression and evaluates its potential as both a biomarker and a therapeutic target.MethodsWe assessed FAM111B expression and function using in vitro and in vivo PCa models. Quantitative PCR, Western blotting, and immunofluorescence assays were employed to determine FAM111B’s effects on apoptosis and on the MAPK signaling cascade. Rescue experiments were performed to elucidate ATF3’s involvement in mediating FAM111B-driven changes in PCa progression.ResultsFAM111B levels were significantly elevated in PCa cell lines and patient-derived tumor tissues. Mechanistically, FAM111B downregulated ATF3, thereby diminishing ATF3’s occupancy at the KRAS promoter. This reduction led to upregulated KRAS expression and enhanced activation of the RAF1–MEK–ERK pathway, which in turn inhibited apoptosis and promoted PCa cell survival. Conversely, FAM111B knockdown increased apoptotic markers, while its overexpression activated MAPK signaling and suppressed pro‑apoptotic factors.ConclusionsOur findings demonstrate that FAM111B drives PCa progression by repressing ATF3 and activating the MAPK pathway to inhibit apoptosis. These results position FAM111B as a promising biomarker and a potential therapeutic target, especially in castration‑resistant prostate cancer (CRPC).Supplementary InformationThe online version contains supplementary material available at 10.1186/s12935-025-04111-3.Keywords: Prostate cancer, Apoptosis, FAM111B, ATF3, Biomarker Introduction Prostate cancer (PCa) is the second most common cancer among men globally, with its incidence significantly influenced by geography, race, lifestyle, and healthcare access [1]. Between 2015 and 2020, new PCa cases in China increased by 60%, while mortality rose by 89% [2]. Although progress has been made in understanding PCa mechanisms, including tumor metabolic programming [3] and programmed cell death [4], the precise pathways driving PCa progression require further investigation. FAM111B, a member of the FAM111 protein family, encodes a protein with a trypsin-like serine protease domain [5]. Mutations in FAM111B are associated with Hereditary fibrosis Poikiloderma with Tendon Contractures, Myopathy, and Pulmonary Fibrosis (POIKTMP syndrome) [6]. This protein is implicated in DNA repair [7], cell cycle regulation [8], and apoptosis [9], and its overexpression correlates with poor outcomes in various cancers [7]. In hepatocellular carcinoma, FAM111B enhances proliferation, invasion, epithelial-mesenchymal transition (EMT), and metastasis through the TACC3/PI3K/AKT signaling pathway [10]. However, its role in PCa progression remains largely undefined. ATF3, part of the ATF/CREB transcription factor family, regulates gene expression via a basic leucine zipper (bZIP) domain [11]. It governs cell proliferation [12], apoptosis [13], metabolism, and immune responses [14]. In PCa, ATF3 inhibits androgen receptor (AR) activity, impacting androgen-independent cancer development [15], However, the specific mechanisms of ATF3 in PCa progression remain unclear. The Mitogen-Activated Protein Kinase (MAPK) signaling pathway is essential for cellular responses to growth factors, cytokines, and stress signals [16–18]. Comprising the RAS, RAF, MEK, and ERK gene families, it regulates metabolic reprogramming and programmed cell death [19]. In PCa, MAPK activation promotes androgen receptor (AR) expression, sustaining tumor growth after androgen deprivation therapy (ADT) [20]. and upregulates anti-apoptotic genes like BCL2, enhancing resistance to chemotherapy [21]. Our study identifies FAM111B as a critical prognostic factor for PCa, closely linked to immune cell interactions in the tumor microenvironment through WGCNA analysis. Functionally, FAM111B enhances PCa cell proliferation, invasion, and metastasis by suppressing apoptosis. Mechanistically, it represses ATF3 expression, thereby activating the MAPK signaling pathway and promoting tumor progression. Methods Dataset Gene expression and clinical trait data for the PRAD cohort can be accessed from the TCGA database via the UCSC Xena Browser [22]. LM22 matrix data is available for download from the official CIBERSORT website [23]. The prostate cancer cohort data for GSE3325 can be retrieved from the GEO database [24]. Bioinformatics analysis Gene expression and clinical data for the PRAD cohort were obtained from the TCGA database and processed using the ‘DESeq2’ R package to identify differentially expressed genes (DEGs) (|fold change| >1, P < 0.05). The LM22 matrix was downloaded from the CIBERSORT website, and the ‘e1071’, ‘preprocessor’, and ‘parallel’ R packages were used for CIBERSORT analysis. DEGs and CIBERSORT data were integrated into a Weighted Gene Co-Expression Network Analysis (WGCNA), with a soft threshold of 9, clustering DEGs into nine modules. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses of the red module were conducted using DAVID [25], with key cellular immunity and proliferation pathways visualized using bubble plots in GraphPad Prism 9. Red module genes were further analyzed for protein-protein interactions (PPI) using STRING [26], and Gene Set Enrichment Analysis (GSEA) [27, 28] was performed to explore metabolic pathways, highlighting intersections with the cell cycle, DNA replication, and proteolysis pathways via Venn diagrams. These analyses identified FAM111B as a candidate gene. Receiver Operating Characteristic (ROC) curves were generated to evaluate FAM111B’s diagnostic value in distinguishing PCa tissues from normal tissues. PCa patients were stratified into high- and low-FAM111B expression groups, with Kaplan-Meier (K-M) curves illustrating disease-free survival (DFS) differences between these groups. FAM111B expression and prognostic analyses in the GSE3325 dataset followed a similar workflow. The top eight DEGs, alongside FAM111B, were subjected to univariate Cox regression analyses using the ‘survival’, ‘forest plot’, and ‘tidyverse’ R packages. Prostate cancer tissue specimen acquisition Tumor and adjacent non-tumor tissues were collected from 18 pairs of PCa patients at the People’s Hospital of Wuhan University. All patients were treatment-naive prior to surgery. The study was approved by the Human Ethics Committee of Wuhan University (Approval Letter number: WDRY2024-KL166, Date 2024-07-25) and conducted in compliance with the Declaration of Helsinki. Culture of prostate epithelial cells and PCa cell lines The prostate epithelial cell line RWPE1 and PCa cell lines LNCaP, 22RV1, DU145, PC3, and VCaP were obtained from the American Type Culture Collection (ATCC). RWPE1 cells were cultured in a basal medium supplemented with bovine pituitary extract (BPE) and human recombinant epidermal growth factor (EGF). LNCaP, 22RV1, DU145, and PC3 cells were maintained in the RPMI-1640 medium, while VCaP cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM). Complete media for all cell lines were prepared with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin (100x). All cell lines were maintained at 37 °C in a humidified 5% CO₂ atmosphere. Cell culture, passaging, and freezing were conducted following ATCC guidelines. Detailed information on reagents and materials, including manufacturers and catalog numbers, is provided in Supplementary Table 2. Transfection of plasmids, lentiviruses Plasmids for FAM111B knockdown or overexpression were synthesized by Genecreate, while ATF3 knockdown plasmids were synthesized by Genechem. Transfections into PCa cells were performed using Lipofectamine 2000, following the manufacturer’s protocol. Additionally, a FAM111B knockdown lentivirus was constructed by Genechem. The sequences for shFAM111B and shATF3 are provided below. Target geneSequenceFAM111B-sh1GCTTACATATTATAGCAFAM111B-sh2CAGCTTACATATTATAGCAATF3-shRNAGGCTGTTGTCATACTTCTCATGG RNA extraction and RNA real-time quantitative PCR (RT-qPCR) analysis from patient tissues Cancerous and adjacent non-cancerous tissues from 18 patient pairs were homogenized using a tissue grinder, and total RNA was extracted according to the RNA extraction kit protocol. The extracted RNA was quantified to 1000 ng, mixed with a cDNA synthesis mix, and reverse-transcribed into cDNA. Primers for target genes were designed using the Primer Bank tool [29] and validated with NCBI Primer-BLAST; detailed primer sequences are provided in Supplementary Table 1. RT-qPCR was performed on the Roche LightCycler® 480 Instrument II, with β-actin used as the internal reference gene to evaluate relative target gene expression levels. RNA extraction, reverse transcription, and RT-qPCR procedures for cell lines followed the same protocols as those for tissue samples. Detailed information on reagents and materials, including manufacturers and catalog numbers, is available in Supplementary Table 2. Protein extraction and Western blot (WB) analysis for patient tissues and cells Prostate cancer tissue was processed by grinding, following the RNA extraction protocol. To the protein samples, add RIPA buffer, Protease Inhibitor Cocktail, Phosphatase Inhibitor Cocktail I, and PMSF, then lyse using an ultrasonicator on ice for 30 min. Pre-cool the ultracentrifuge to 4 °C, centrifuge at 10,000 rpm for 10 min, and collect the supernatant, avoiding the pellet. For protein quantification, mix the supernatant with BCA working solution, incubate at 37 °C for 30 min, and measure absorbance at 562 nm. Determine the protein concentration from the BCA standard curve and adjust to 10 ng/µL using RIPA buffer and non-reducing loading buffer. For Western blot, prepare the SDS-PAGE gel using the appropriate kit and load 10 µg/µL of each sample into 15 wells. Run the gel at 80 V until the samples reach the separating gel, then increase to 120 V for 90 min. Activate a PVDF membrane in methanol, then transfer the gel to the membrane at 75 mA for 2 h. After transfer, wash the membrane with TBST, block with 5% skim milk for 1 h, and wash three times with TBST. Incubate with the primary antibody overnight at 4 °C, wash, then incubate with the secondary antibody for 1 h at 4 °C. After washing, detect protein expression using ECL chemiluminescent reagent and capture images. Quantify the bands using ImageJ software, followed by statistical analysis and graphing in GraphPad Prism 9. Primary antibody details are in Table 1, and reagent information is in Supplementary Table 2. Immunohistochemistry (IHC) Wax-embedded tissue blocks were sectioned (4–5 μm), deparaffinized with xylene, and rehydrated in graded alcohol. Antigen retrieval was performed in citrate buffer (pH 6.0) using microwave heating, and endogenous peroxidase activity was quenched with hydrogen peroxide for 10 min. Sections were blocked with 5% goat serum for 30 min at room temperature, incubated overnight at 4 °C with the primary antibody, and washed three times with TBST. After a 30-minute incubation with the secondary antibody at room temperature, sections were washed, developed with DAB, counterstained with hematoxylin, dehydrated, cleared in graded alcohol and xylene, and mounted. Positive staining was evaluated by cell counting and intensity scoring, with image analysis performed in ImageJ and statistical analysis in GraphPad Prism 9. Primary antibody details are in Table 1, and information on reagents and materials, including manufacturers and catalog numbers, is provided in Supplementary Table 2. Cell counting Kit-8 (CCK-8) Prepare the CCK-8 working solution by diluting the stock solution 1:10 with 1640 complete medium. Add 200 µL of the solution to each well of a 96-well plate and seed ~ 2,000 PCa cells per well. Mix thoroughly, and fill the outermost wells with PBS to minimize edge effects. Set up three replicates per group and incubate at 37 °C in a 5% CO₂ incubator for 24, 48, and 72 h. Measure the absorbance at 450 nm using a microplate reader, ensuring readings are taken at the same time each day and that no bubbles are present. Details of primary antibodies are in Table 1, and reagent information, including manufacturers and catalog numbers, is in Supplementary Table 2. Cell clone formation experiment Treated PCa cells were seeded into 6-well plates at ~ 1,000 cells per well and cultured at 37 °C in a 5% CO₂ incubator until visible colonies formed. Media was changed as needed based on color and cell viability. After one week, cells were fixed with 4% paraformaldehyde for 15 min, rinsed three times with PBS, and stained with crystal violet for 20 min. Plates were washed with PBS, and colonies were photographed and counted. Data analysis was performed using GraphPad Prism 9. Details of primary antibodies are in Table 1, and reagent information, including manufacturers and catalog numbers, is in Supplementary Table 2. Cell migration and invasion assay For the cell migration assay, 200 µL of 1640 basal medium was added to the upper chamber of a transwell, and 700 µL of complete medium was added to the lower chamber. Treated PCa cells (~ 40,000 cells/well) were seeded into the upper chamber and incubated at 37 °C with 5% CO₂ for 48 h. After incubation, non-migrated cells in the upper chamber were removed, and the remaining cells were fixed with paraformaldehyde, washed with PBS, and stained with crystal violet. Chambers were air-dried, and migrated cells were counted under a 200x microscope. For the invasion assay, the upper chamber was pre-coated with Matrigel and seeded with ~ 80,000 cells/well in 200 µL of basal medium. The remaining steps were identical to those of the migration assay. Details on reagents and materials, including manufacturers and catalog numbers, are provided in Supplementary Table 2. 5-Ethynyl-2’-deoxyuridine (EDU) assay Treated PCa cells at 50% confluency were incubated with EdU working solution at 37 °C and 5% CO₂ for 1 h. Cells were fixed with 4% paraformaldehyde for 10 min, washed three times with PBS, permeabilized with 0.5% Triton X-100 for 10 min, and washed with 3% BSA. The Click-iT reaction mixture was applied, mixed, and incubated in the dark for 30 min. After three washes with 3% BSA, nuclei were stained with Hoechst dye for 10 min, followed by additional washes. Cells were dried, counted under a microscope, and analyzed using Prism 9. Reagent details, including manufacturers and catalog numbers, are provided in Supplementary Table 2. Wounding healing assay Treated PCa cells were seeded in 6-well plates and cultured at 37 °C with 5% CO₂ until reaching 90%−100% confluency. A wound was created using a 200 µL pipette tip, and cells were gently washed with PBS and replaced with serum-free medium. The initial wound width was recorded under a microscope, and after 24 h of incubation, the wound width was measured again. The healing rate was calculated in ImageJ using the formula: Healing rate = [(Initial width - Current width)/Initial width] × 100%. Statistical analysis was conducted with GraphPad Prism 9. Reagent details, including manufacturers and catalog numbers, are provided in Supplementary Table 2. Terminal deoxynucleotidyl transferase dUTP Nick end labeling (Tunel) Treated cells were seeded on 6-well plate coverslips and incubated to ~ 50% confluence. Cells were fixed with 4% paraformaldehyde for 10 min, permeabilized with 0.3% Triton X-100, and labeled with a dUTP-TdT working solution following kit instructions. Coverslips were transferred to slides, and 10 µL of the working solution was applied, followed by a 30-minute incubation in the dark. After three washes with BSA, samples were stained with DAPI for 15 min to visualize nuclei, washed again, air-dried, and observed under a 200x fluorescence microscope. TUNEL-positive cells exhibited green fluorescence, while DAPI-stained nuclei appeared blue. The percentage of TUNEL-positive cells was calculated as TUNEL-positive cells/total DAPI-stained cells, with statistical analysis performed using GraphPad Prism 9. Reagent details, including manufacturers and catalog numbers, are listed in Supplementary Table 2. Immunofluorescence localization Immunofluorescence involves fixing cells with 4% paraformaldehyde, permeabilizing with 0.1%−0.3% Triton X-100, and blocking nonspecific binding with 5%−10% normal serum. Primary antibodies are applied and incubated at 4 °C overnight or at room temperature for 1–2 h, followed by three washes with PBS. Fluorescently labeled secondary antibodies are then added and incubated for 1 h in the dark, followed by additional washes. Nuclei are stained with DAPI or Hoechst for 5–10 min. Samples are mounted with an antifade mounting medium and visualized under a fluorescence or confocal microscope. Apoptosis flow cytometry Processed PCa cells were digested with EDTA-free trypsin, washed three times, and 10⁵–10⁶ cells were collected. Annexin V binding buffer was diluted 1:10 with deionized water to prepare the working solution. Cells were resuspended in the working solution, and Annexin V and PI dyes were added. After gentle mixing, samples were incubated for 15 min at room temperature in the dark. Subsequently, 400 µL of working solution was added to each tube for dilution. Flow cytometry was performed, detecting Annexin V in the FITC channel and PI in the PE channel, with at least 10,000 events collected per sample.Results were classified as follows: Annexin V-/PI- (live cells). Annexin V+/PI- (early apoptotic cells). Annexin V+/PI+ (late apoptotic/necrotic cells). Annexin V-/PI+ (necrotic cells). Data were analyzed using flow cytometry software with three replicates per group, and statistical analysis was performed in GraphPad Prism 9. Details of reagents and materials, including manufacturers and catalog numbers, are provided in Supplementary Table 2. CHIP-qPCR Harvest 1 × 107–1 × 108 DU145 cells and crosslink by adding formaldehyde to 1% final concentration, incubating at 37 °C with gentle agitation for 10 min, then quench with 125 mM glycine for 5 min. Wash twice with ice‑cold PBS, lyse in cell lysis buffer (with protease inhibitors) on ice for 10 min, and pellet nuclei by centrifugation. Resuspend nuclei in sonication buffer and fragment chromatin to 200–500 bp using 30 s ON/30 s OFF cycles for 8–10 cycles; clarify by centrifugation. Pre‑clear the supernatant with Protein A/G beads for 1 h at 4 °C, transfer to a fresh tube, then incubate overnight at 4 °C with 1–5 µg of ATF3 antibody or IgG control and subsequently add Protein A/G beads for 2 h. Wash sequentially (low‑salt, high‑salt, LiCl, and twice TE buffer) at 4 °C for 5–10 min each, then elute twice with 1% SDS/0.1 M NaHCO₃ for 15 min at room temperature. Combine eluates, reverse crosslinks at 65 °C for 4–6 h (or overnight), treat with RNase A (37 °C, 30 min) and Proteinase K (55 °C, 1 h), and purify DNA via phenol–chloroform extraction or a column kit, eluting in TE buffer. Finally, perform PCR. The PCR primer sequence is KRAS forward 5′:-TCACAA GCC TCC TGA CCC G-3′, and reverse 5′-GAA GCT GCG AAG AGC ACC C-3′. Experimental mice subcutaneous loaded tumor experiments Animal experiments were approved by the Animal Ethics Committee of the People’s Hospital of Wuhan University (Ethics No. WDRM 20240302 A, Date 2024-03-08). FAM111B or ATF3 knockdown PCa cell lines were prepared using lentivirus and resuspended in PBS (1 × 10⁶–5 × 10⁶ cells/100 µL). Cells were injected into the right dorsal side of 4-week-old mice (purchased from Cyagen Corporation) using a microsyringe. Mice were housed under SPF conditions in the Animal Biosafety Level 3 Laboratory of Wuhan University. Tumor growth was monitored every 3 days for ~ 15 days, and tumor volume was calculated as (L × W²)/2. Body weight was also recorded to assess overall health. At the endpoint, mice were euthanized, and tumors were excised, weighed, photographed, and processed for IHC, TUNEL staining, and statistical analysis using GraphPad Prism 9. Statistical analysis Data from TCGA-PRAD and GEO-PRAD datasets, representing FAM111B expression in normal and tumor samples, were presented as mean ± SD. Statistical analysis was performed using Student’s t-test (paired/unpaired) in GraphPad Prism 9. Clinical characteristics were analyzed with the Pearson chi-square test, while DFS and one-way Cox regression were assessed in SPSS 25.0, with significance set at P < 0.05 (two-tailed). Biological experiments were conducted in triplicate, and bar graphs were created in GraphPad Prism 9. Hypothetical mechanism diagrams were generated using Figdraw 2.0. Significance levels: *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. Error bars indicate mean ± SEM. Results 1. Hub modules of PCa and tumor immunity identified by WGCNA analysis Gene expression counts from the TCGA-PRAD cohort were analyzed using the ‘DESeq2’ R package, identifying 6,640 differentially expressed genes (DEGs) (|fold change| >1, P < 0.05), including 3,503 upregulated and 3,137 downregulated genes (Fig. 1A). The DEGs were further processed using the ‘WGCNA’ package to construct a weighted gene co-expression network. A gene dendrogram with module colors was generated (Fig. 1B), and a soft threshold of 9 was applied (Fig. 1C). Clustering analysis grouped DEGs into nine hub color modules (Fig. 1D), with the relationship between these modules and tumor immune characteristics shown in Fig. 1E. The red module demonstrated strong correlations with stromal score, immune score, estimate score, and tumor purity (Fig. 1F). Protein-protein interaction (PPI) network analysis of red module genes was conducted using STRING database (Fig. 1G). Gene Ontology (GO)/KEGG enrichment analysis via DAVID revealed that red module genes were primarily involved in tumor immunity and the ERK1/2 cascade pathway (Fig. 1H). Bioinformatics identifies hub genes in prostate cancer. (A) Volcano map presentation of 6640 differential genes in prostate cancer. (B) The gene dendrogram and module colors of DEGs via TOM. (C) Variation of scale-free topology and mean connectivity under different soft thresholds. (D) clustering of module eigengenes of DEGs. (E) Relationship between the nine modules and immune infiltration via WGCNA. (F) Scatterplot of the 4 immune infiltration assessment metrics with corresponding color Red module. (G) Red Module Gene Interaction Network Analysis of PPI Proteins via string. (H) GO analysis of TOP10 of the red gene module 2. FAM111B as a prognostic biomarker and immune microenvironment modulator in prostate cancer Gene set enrichment analysis (GSEA) identified key pathways related to proliferation, including the cell cycle, DNA replication, and DNA-protein complex formation, which were intersected with red module genes to highlight FAM111B as a potential target (Fig. 2A). Analysis of the TCGA-PRAD cohort revealed significantly higher FAM111B expression in tumor tissues compared to paraneoplastic tissues, as well as in advanced-stage patients (Fig. 2, B-D). Diagnostic analysis revealed a strong value for FAM111B in PCa (AUC = 0.756, p < 0.05), validated in the GEO GSE3325 dataset (Fig. 2, E-H). High FAM111B expression correlated with advanced tumor stage, higher Gleason scores, and poorer disease-free survival (DFS) (Figs. 2, I-L). Immune scores and tumor purity were assessed using the ‘estimate’ R package, showing correlations between red module genes and tumor-infiltrating immune cells (Figures S1, A-B). FAM111B and EZH2 were linked to immune cell populations through single-sample GSEA (ssGSEA) (Figure S1, C-D), positively correlating with active CD4 T cells and CD86 (Figure S2, A, C) and negatively with PDCD1 and CCL2 (Figure S2, B, D). Furthermore, FAM111B also associated with immune subgroups (C1-C4) and transcription factors but showed no correlation with HLA antigens or chemokine receptors (Figure S2, E-H). One-way Cox regression identified FAM111B as an independent prognostic factor for PCa progression (Fig. 2M). In vitro analysis confirmed higher FAM111B mRNA and protein levels in PCa cell lines, especially DU145 and PC3 (Figs. 2, N-P). These findings were validated in patient samples from Wuhan University, where elevated FAM111B expression was observed in 14 of 18 cases (Fig. 2Q), consistent with immunohistochemistry (IHC) results (Figs. 2, R-S). FAM111B is highly expressed in prostate cancer and strongly associated with poor prognostic survival. (A) The Venn diagram of the Red module, cell cycle, DNA replication, protein DNA complex, and Proteolysis-related genes. (B-D) FAM111B expression levels in TCGA in normal versus tumor patients, in cancer versus paraneoplastic in the same patient, and in normal versus patients with various stages of the disease. (E) ROC curve for Subjects in the PCa Cohort in TCGA. (F-G) FAM111B expression levels in GSE3325 in normal versus tumor patients and in normal versus patients with various stages of the disease. (H) ROC curve for Subjects in the PCa Cohort in GSE3325. (I-K) Association of FAM111B expression level with tumor analysis, Gleason score, and time to recurrence using chi-square analysis. (L) K-M curves for PCa pair column disease-free survival in TCGA. (M) One-way COX regression analysis and forest plot for the TOP 10 genes in the red module. (N) FAM111B relative mRNA expression levels in PrSC, RWPE1, LNCaP, DU145, PC3 cell lines. (O-P) WB of FAM111B and quantitative analysis relative protein expression levels in PrSC, RWPE1, LNCaP, DU145, PC3 cell lines. (Q) FAM111B relative expression in cancer and paracancerous tissues of 18 Wuhan University People’s Hospital clinical patients. (R) WB of FAM111B in cancer and paracancerous tissues of 18 Wuhan University People’s Hospital clinical patients. (S) FAM111B staining in cancer and para cancer IHC in 2 Wuhan University People’s Hospital patients 3. FAM111B drives prostate cancer progression by enhancing Proliferation, Migration, and invasion Elevated epidermal growth factor (EGF) levels in the tumor microenvironment (TME), including in PCa, are known to promote oncogene expression and tumor progression [30]. Gene expression correlation analysis (GIPEA) analysis of the TCGA-PRAD cohort revealed a positive correlation between FAM111B and EGFR expression (Figure S3A). Western blot analysis in DU145 and PC3 cells treated with increasing EGF concentrations showed upregulation of FAM111B (Figure S3B), indicating that EGF induces FAM111B expression in PCa. FAM111B knockdown in DU145 and PC3 cells, confirmed by PCR and WB (Fig. 3, A-C), reduced cell proliferation as demonstrated by CCK-8, colony formation, and EdU assays (Fig. 3, D-G, I). Additionally, transwell and wound healing assays showed decreased cell migration and invasion following FAM111B knockdown (Fig. 3, H-J, K). Conversely, FAM111B overexpression, validated by PCR and WB (Figs. 4, A-C), markedly enhanced proliferation, migration, and invasion, as shown in CCK-8, EdU, colony formation, transwell, and wound healing assays (Figs. 4, D-K). These findings highlight FAM111B as a key driver of PCa progression, promoting proliferation, migration, and invasion via interaction with the TME and activation of EGFR signaling. Knockdown of FAM111B expression inhibits proliferation and invasiveness of prostate cancer cell lines. (A-C) The DU145, PC3 cell line was transfected by plasmids, and the transcript level and protein expression level of FAM111B were detected using qPCR and WB. (D-E) PCa cell proliferation was detected using the CCK8 kit after the knockdown of FAM111B expression. (F) PCa cell proliferation was detected using a clonal plate assay in the FAM111B expression knockdown. (G, I) Evaluation of PCa proliferative capacity using EDU assay after the knockdown of FAM111B. (H) When FAM111B expression was inhibited, the transwell assay detected the proliferation and invasive ability of PCa cells. (J-K) PCa migration capacity was assessed using the wound healing assay when FAM111B expression was knocked down Overexpression of FAM111B expression promotes proliferation and invasiveness of prostate cancer cell lines. (A-C) The DU145, PC3 cell line was transfected by plasmids, and the transcript level and protein expression level of FAM111B were detected using qPCR and WB. (D-E) PCa cell proliferation was detected using the CCK8 kit after the overexpression of FAM111B expression. (F) PCa cell proliferation was detected using a clonal plate assay in the overexpression of FAM111B. (G) Evaluation of PCa proliferative capacity using EDU assay after the overexpression of FAM111B. (H-I) When FAM111B expression was overexpressed, the proliferation and invasive ability of PCa cells were detected by the transwell assay. (J-K) PCa migration ability was assessed using the wound healing assay when FAM111B expression was overexpressed 4. FAM111B regulates prostate cancer progression through MAPK pathway activation and apoptosis suppression Knocking down FAM111B in DU145 cells identified 551 upregulated and 181 downregulated genes via transcriptomic sequencing. GO enrichment analysis of the upregulated genes highlighted a strong association with the MAPK signaling pathway (Fig. 5A). Analysis using GEPIA confirmed a positive correlation between FAM111B expression and MAPK pathway-related genes (Fig. 5B). FAM111B knockdown reduced KRAS and BCL2 expression while increasing BAX, as shown by qPCR (Fig. 5C). Western blot revealed decreased KRAS expression, suppressed RAF1-MEK-ERK phosphorylation, and increased levels of BAX and Cleaved caspase-3, promoting apoptosis (Fig. 5D). Apoptosis induction was further validated through TUNEL assays and flow cytometry, which showed significantly elevated apoptosis in FAM111B-silenced cells (Fig. 5, E-G). Conversely, FAM111B overexpression activated the MAPK pathway, increasing KRAS and BCL2 expression levels, reducing BAX, and enhancing phosphorylation of RAF1, MEK, and ERK (Fig. 6, A-B). TUNEL assays and flow cytometry showed reduced apoptosis with FAM111B overexpression (Fig. 6, C-D). Rescue experiments using MAPK activator ML-099 restored suppressed signaling in FAM111B knockdown cells by increasing phosphorylation of RAF1, MEK, and ERK, lowering BAX and Cleaved caspase-3 levels, and elevating BCL2 expression (Fig. 6, E-G). These findings identify FAM111B as a key promoter of PCa progression by activating the MAPK pathway and inhibiting apoptosis. Knockdown of FAM111B expression inhibits MAPK signaling pathway transduction to promote PCa cell apoptosis. (A) Transfection of DU145 cells using plasmids knocked down FAM111B expression. Cell samples were sent for transcriptome sequencing to obtain DEGs. The DEGs were subjected to GO analysis and the TOP20 signaling pathway was selected (B) Scatter plot of correlation between FAM111B gene and genes downstream of MAPK signaling axis. (C-D) Changes in transcription levels and translation levels of genes downstream of the MAPK signaling pathway after inhibition of FAM111B expression. (E-F) PCa cell apoptosis was detected using the Tunel kit when FAM111B expression was inhibited. (G) Number of PCa cell apoptosis detected by flow cytometry using an apoptosis kit when FAM111B expression was suppressed FAM111B promotes PCa progression by regulating the MAPK signaling pathway. (A) Expression of genes downstream of the MAPK signaling pathway axis when FAM111B is overexpressed. (B) WB analysis of MAPK signaling pathway downstream genes after FAM111B overexpression. (C) Detect PCa cell apoptosis after FAM111B overexpression via Tunel kit. (D) Apoptosis of PCa cells overexpressing FAM111B detected by flow cytometry. (E) The MAPK pathway was activated using ML-099 in PCa cells knocked down for FAM111, and protein levels of genes downstream of the MAPK pathway were detected. (F-G) Detection of apoptosis in the above PCa cells using flow cytometry with the Tunel kit 5. FAM111B promotes prostate cancer progression by suppressing ATF3 expression Transcriptome sequencing after FAM111B knockdown identified 551 upregulated and 181 downregulated genes (Fig. 7A), with top upregulated genes including IGFBP3, ATF3, NDRG1, ERRFI1, and SERPINE1 (Fig. 7B). GO enrichment analysis highlighted associations with apoptosis, programmed cell death, and the MAPK pathway, identifying ATF3 as a key gene (Fig. 7C). ATF3 expression was validated in DU145 cells and correlated with TCGA-PRAD data, showing elevated levels in tumor tissues and an association with high Gleason scores (Fig. 7, D-F). ROC analysis confirmed ATF3 as a diagnostic marker for PCa (Fig. 7G), and IHC from patient samples corroborated these findings (Fig. 7H). FAM111B modulation in DU145 and PC3 cells revealed an inverse relationship with ATF3 protein levels via Western blot (Fig. 7I). Rescue experiments showed that shATF3 counteracted the effects of FAM111B knockdown, restoring PCa cell proliferation, migration, and invasion (Fig. 7, J-O). FAM111B promotes PCa progression by inhibiting ATF3. The transfected PCa cell lines were transfected using a plasmid. After determining the effect of FAM111B knockdown using qPCR, the transfected PCa cell lines were subjected to transcriptome sequencing (A) Volcano plot of DEGs after transcriptome sequencing following FAM111B knockdown. (B) Top 5 gene Heatmap of FAM111B associated DEGs. (C) Venn diagram of the GO/KEGG signaling pathway. (D) ATF3 expression in DU145 PCa cell sequencing results. (E-F) ATF3 expression in normal versus tumor patients and gleason7/8/9/10 scoring PCa patients in the PRAD cohort of the TCGA database. (G) ROC curves for PRAD in the TCGA database. (H) Immunohistochemistry of ATF3 in cancer and paracancerous tissues of four patients at Wuhan University People’s Hospital, Wuhan, China. (I) WB analyses of FAM111B and ATF3 were performed when FAM111B-expressing interfered. (J) WB analyses of FAM111B and ATF3 were performed when FAM111B or ATF3-expressing interfered (K) Assaying the proliferative capacity of each group of cells using the CCK8 kit. (L-M) The proliferative ability of the above cells was assayed using the EDU kit and cloning plate assays. (N-O) wound healing assay and transwell assay to detect PCa cells’ ability to migrate and invade 6. ATF3 suppresses prostate cancer progression by regulating the KRAS-MAPK pathway and promoting apoptosis These findings suggest that FAM111B promotes PCa progression by suppressing ATF3 expression and activating the MAPK signaling pathway. As ATF3 is a transcriptional regulator, we hypothesized that FAM111B inhibits ATF3, counteracting its suppression of the MAPK pathway. Analysis of the KRAS promoter sequence (Supplementary Table 3) using GTRD [31], identified a potential ATF3 binding site (Supplementary Table 4), suggesting ATF3 may inhibit MAPK activation and PCa progression. This suggests that ATF3 may suppress MAPK pathway activation and PCa progression. Immunofluorescence co-localization of FAM111B and ATF3 further supported the possibility of their interaction (Figure S3C). Rescue experiments supported this hypothesis. WB analysis showed that ATF3 inhibition increased KRAS expression, phosphorylation of RAF1, MEK, and ERK, and anti-apoptotic BCL2 levels, while pro-apoptotic markers BAX and cleaved caspase-3 decreased. MCP110, a MAPK pathway inhibitor, reversed these effects, restoring apoptosis (Fig. 8A). CCK-8, colony formation, and EdU assays showed reduced proliferation in MCP110-treated, ATF3-inhibited PCa cells (Fig. 8, B-D), while transwell, TUNEL, and flow cytometry assays confirmed diminished migration, invasion, and enhanced apoptosis (Fig. 8, E-G). Consistently, ChIP-PCR assay confirmed the enrichment of ATF3 at the KRAS promoter (Fig. 8, H-I). Based on these results, we performed luciferase reporter assays with WT plasmid carrying the KRAS promoter sequence, or MU plasmid in which the ATF3 binding motif was disrupted. The luciferase activity was enhanced in WT plasmid-transfected cells, while the promoting effect was abrogated in MU plasmid-transfected cells (Fig. 8J), suggesting that KRAS is a direct transcription target of ATF3. Gene Set Cancer Analysis (GSCA) revealed that mutations and methylation of FAM111B and ATF3 were closely linked to PCa progression (Figures S3, D-E). Drug sensitivity analysis using GDSC [32, 33]and CTRP identified potential therapeutic targets (Figures S3, F-G). In summary, ATF3 suppresses PCa progression by binding the KRAS promoter, inhibiting MAPK activation, and promoting apoptosis. FAM111B downregulates ATF3, enhancing MAPK activity and tumor progression. FAM111B inhibits ATF3 to activate MAPK signaling pathway, inhibits apoptosis, and promotes PCa progression. PCa cells were transfected with ATF3 shRNA, and MCP110 was used to inhibit the MAPK pathway in PCa cells. (A) WB analysis of FAM111B, ATF3, and MAPK signaling pathway downstream genes in the above PCa cell. (B-D) The proliferative capacity of the above cells was assayed by EDU using the CCK8 kit, cloning plate assay. (E) Transwell assay was used to detect the migration and invasion ability of the above cell. (F) Detection of apoptosis in the above cells using the Tunel kit. (G) Flow cytometry to detect apoptosis in the above cells. (H) Bioinformatic analysis of ATF3 binding sequence in the promoter region of KRAS. (I) CHIP-qPCR was performed in DU145 to identify the enrichment of ATF3 on KRAS promoter region. (J) Dual luciferase reporter analysis in DU145 7. FAM111B inhibits the ATF3/KRAS/RAF axis, leading to MAPK pathway activation, apoptosis suppression, and enhanced PCa progression in vivo To validate FAM111B’s role in vivo, a subcutaneous xenograft model was established. FAM111B knockdown significantly reduced tumor size, while shATF3 reversed this effect, restoring tumor growth (Fig. 9, A-C). IHC analysis revealed that FAM111B inhibition elevated ATF3 expression, suppressed MAPK signaling (reduced P-MEK and P-ERK), decreased Ki-67, and increased pro-apoptotic markers (BAX and cleaved caspase-3). TUNEL staining confirmed increased apoptosis and reduced PCa progression. In the shFAM111B + shATF3 group, MAPK and apoptosis-related markers were restored (Fig. 9D). These results suggest that elevated EGF levels in the tumor microenvironment promote FAM111B expression, which suppresses nuclear ATF3, reducing its binding to the RAS promoter. This leads to upregulated KRAS expression and activation of the RAF1-MEK-ERK signaling cascade, inhibiting apoptosis by increasing anti-apoptotic proteins (BCL2) and suppressing pro-apoptotic proteins (BAX and cleaved caspase-3). The combined effects of apoptosis inhibition and enhanced proliferation drive tumor growth and PCa progression (Fig. 9E). FAM111B/ATF3/KRAS axis promotes the MAPK signaling pathway, inhibiting apoptosis and promoting PCa progression in vivo. (A-B) Statistical graphical analysis of tumor photographs and weights in control, shATF3, shFAM111B, shFAM111B + shATF3 groups (n = 5). (C) Tumor volume growth line graph for the above groups (n = 5). (D) Expression of FAM111B, ATF3, Ki67, Tunel, P-MEK, MEK, P-ERK, ERK, BAX, BCL2, and Cleaved caspase 3 genes was assessed using immunohistochemistry in the above 4 groups of tumors (n = 3). (E) Inhibition of PCa cell apoptosis by FAM111B/ATF3/KRAS axis promotes PCa progression Discussion Prostate cancer (PCa) is a common and increasingly fatal malignancy in men, with many Chinese patients diagnosed at advanced stages or with CRPC [34]. Androgen deprivation therapy (ADT) becomes less effective in CRPC [35], where reactivation of the androgen receptor (AR) and aberrant MAPK signaling are key drivers of tumor growth via hormone-independent mechanisms [36]. ATF3, a regulator of the MAPK pathway, exhibits dual effects by either activating downstream targets or inhibiting the KRAS/RAF/ERK axis, influencing cell proliferation, apoptosis, and stress responses [37]. This study demonstrates that FAM111B promotes PCa progression by suppressing ATF3 expression, activating the MAPK pathway, inhibiting apoptosis, and driving tumor growth, highlighting the interplay between FAM111B, ATF3, and MAPK signaling. FAM111B, a member of the FAM111 gene family, encodes a protein with a trypsin-like serine protease domain, playing roles in cell proliferation, apoptosis, DNA repair, and protein stability [38]. Overexpression of FAM111B has been linked to several cancers, including hepatocellular carcinoma [39], thyroid cancer [40], and PCa [5], promoting tumor progression via pathways regulating proliferation, invasion, and metastasis. It is also associated with apoptosis-related genes like BCL2 and BAX [41]. This study identified that FAM111B directly interacts with ATF3, reducing its expression and preventing ATF3 from binding to the KRAS promoter, leading to MAPK pathway activation. This activation suppresses apoptosis and drives PCa progression, underscoring FAM111B’s role in modulating ATF3, MAPK signaling, and apoptosis as a potential therapeutic target. Apoptosis, a tightly regulated process of programmed cell death, is essential for growth, tissue homeostasis, and immune regulation [42]. Unlike necrosis, apoptosis is a non-inflammatory process marked by specific molecular and morphological changes [43]. Dysregulation of apoptosis-related genes contributes to tumor progression in cancers like breast cancer [44] and hepatocellular carcinoma [45]. By evading apoptosis, tumor cells achieve unchecked growth and proliferation. Our findings reveal that FAM111B inhibits apoptosis in PCa by upregulating KRAS expression and activating the RAF-MEK-ERK axis, suggesting its potential as a therapeutic target. In conclusion, FAM111B is closely associated with PCa clinical features and exhibits strong diagnostic potential, as identified through bioinformatics analyses such as WGCNA. In vivo and in vitro studies confirmed FAM111B’s role in PCa progression, showing that it suppresses ATF3 expression, reduces ATF3 binding to the KRAS promoter, and activates the MAPK signaling pathway. These mechanisms inhibit apoptosis and promote tumor growth, making FAM111B a promising biomarker and therapeutic target for PCa management. Supplementary Information Supplementary Material 1 Supplementary Material 2 Supplementary Material 3 Supplementary Material 4 Supplementary Material 5 Author contributions Weimin Yu and Fan Cheng designed the experiments. Yanan Wang, Zefeng Wang, Zhen Yin, Tianbao Song, Yipeng He, Ming Li, Zitao Wang, Zhongze Li, and Peihan Wang generated the methods, performed the experiments, and collected the data. Yanan Wang, Zefeng Wang and Zhen Yin performed the data analysis and wrote the original manuscript. Zhiquan Hu, Zhihua Wang, Weimin Yu, and Fan Cheng revised the manuscript. Funding This study was supported by the Natural Science Foundation of China (grant nos. 82372966, 82300766 and 82100806). Data availability No datasets were generated or analysed during the current study. Declarations Ethics approval and consent to participate The Institutional Review Board of Renmin hospital of Wuhan University has approved our research procedures (number: WDRY2024-K166). Consent for publication All authors agree to submit the article for publication. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Yanan Wang, Zefeng Wang and Zhen Yin contributed equally to this work. Contributor Information Weimin Yu, Email: ywm.com.cn@163.com. Fan Cheng, Email: urology1969@aliyun.com. References Associated Data Supplementary Materials Supplementary Material 1 Supplementary Material 2 Supplementary Material 3 Supplementary Material 4 Supplementary Material 5 Data Availability Statement No datasets were generated or analysed during the current study.